Let's look at a closer comparables that I found in my DD process

Cannabis Science- (OTC: CBIS)
$68m MARKET Cap (high of $220m!)

* NO platform technolgy
* NO Breeding & Culivation department
* Avg. mgmt team at best
* Share structure is abysmal...750m I/O!!
* Only two products in Pre-clinical!

Cannabis Technologies (C: CSE)
$14m Market Cap

* Valuable propietary Technology Platform
* Breeding & Cultivation Division
* Mgmt with track record of drug development to commercialization
* Excellent structure...36m I/O
* Product pipleine....not sure what's coming..but...has to be big based on credentailas of Dr. H!

Already have shown, Phase 1 Glaucoma Human Trials on 1st Therapy so this company truly is only still in its infancy.

GWPH did an IPO for $8.90 a share last May and the stock hit a high of $107 a share, obviously i'm not saying CAN is going there anytime soon but its not out of the realm of possibility within the next 3 to 5 years.

Read up on Dr.Sazzad's credentials, anything is possible...i'm sure people we're laughing at GWPH a few years ago and now look at them.